US11564933B2 - Methods of treating testosterone deficiency - Google Patents
Methods of treating testosterone deficiency Download PDFInfo
- Publication number
- US11564933B2 US11564933B2 US16/382,835 US201916382835A US11564933B2 US 11564933 B2 US11564933 B2 US 11564933B2 US 201916382835 A US201916382835 A US 201916382835A US 11564933 B2 US11564933 B2 US 11564933B2
- Authority
- US
- United States
- Prior art keywords
- subject
- pharmaceutical composition
- testosterone
- oral pharmaceutical
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Definitions
- Testosterone is a primary androgenic hormone produced in the interstitial cells of the testes and is responsible for normal growth, development and maintenance of male sex organs and secondary sex characteristics (e.g., deepening voice, muscular development, facial hair, etc.). Throughout adult life, testosterone is necessary for proper functioning of the testes and its accessory structures, prostate and seminal vesicle; for sense of well-being; and for maintenance of libido, erectile potency.
- Testosterone deficiency insufficient secretion of T characterized by low total T concentrations—can give rise to medical conditions (e.g., hypogonadism) in males. Symptoms associated with male hypogonadism include impotence and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics, decreased muscle mass, and increased fat mass. Furthermore, hypogonadism in men is a risk factor for osteoporosis, metabolic syndrome, type II diabetes and cardiovascular disease.
- testosterone replacement therapies are commercially available for the treatment of male hypogonadism.
- Pharmaceutical preparations include both testosterone and testosterone derivatives in the form of intramuscular injections, implants, oral tablets of alkylated T (e.g., methyltestosterone), topical gels, topical patches, or an intranasal gel.
- alkylated T e.g., methyltestosterone
- testosterone undecanoate which has the following chemical structure:
- a formulation of testosterone undecanoate has been reported in the FDA approved drug label JATENZO®.
- the formulation also includes oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, and butylated hydroxytoluene.
- a method of treating conditions associated with a deficiency or absence of endogenous testosterone in a subject in need thereof who has adequately controlled blood pressure comprising: administering daily to the subject a defined dose of an oral pharmaceutical composition comprising testosterone undecanoate in a carrier comprising at least one lipophilic surfactant and at least one hydrophilic surfactant.
- any one of the listed items can be employed by itself or in combination with any one or more of the listed items.
- the expression “A and/or B” is intended to mean either or both of A and B, i.e. A alone, B alone or A and B in combination.
- the expression “A, B and/or C” is intended to mean A alone, B alone, C alone, A and B in combination, A and C in combination, B and C in combination or A, B, and C in combination.
- High blood pressure stage 1 is characterized by a systolic blood pressure of between 130 and 139 mm Hg or a diastolic blood pressure of 80-90 mm Hg.
- High blood pressure stage 2 is characterized by a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher.
- antihypertensive therapy refers to medications to treat high blood pressure, including without limitation:
- antihypertensive therapy refers to valsartan, metoprolol, valsaran/HCTZ, olmesartan/HCTZ, lisinopril, amlodipine, or hydrochlorothiazide.
- co-administer and “co-administration” and variants thereof mean the administration of at least two drugs to a patient either subsequently, simultaneously, or consequently proximate in time to one another (e.g., within the same day, or week or period of 30 days, or sufficiently proximate that each of the at least two drugs can be simultaneously detected in the blood plasma).
- two or more active agents can be co-formulated as part of the same composition or administered as separate formulations. This also may be referred to herein as “concomitant” administration or variants thereof.
- adjusting administration As used herein, “adjusting administration”, “altering administration”, “adjusting dosing”, or “altering dosing” are all equivalent and mean tapering off, reducing or increasing the dose of the substance, ceasing to administer the substance to the patient, or substituting a different active agent for the substance.
- administering to a patient refers to the process of introducing a composition or dosage form into the patient via an art-recognized means of introduction.
- an agent, compound, drug, composition or combination is an amount which is nontoxic and effective for producing some desired therapeutic effect upon administration to a subject or patient (e.g., a human subject or patient).
- the precise therapeutically effective amount for a subject may depend upon, e.g., the subject's size and health, the nature and extent of the condition, the therapeutics or combination of therapeutics selected for administration, and other variables known to those of skill in the art. The effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician.
- informing means referring to or providing published material, for example, providing an active agent with published material to a user; or presenting information orally, for example, by presentation at a seminar, conference, or other educational presentation, by conversation between a pharmaceutical sales representative and a medical care worker, or by conversation between a medical care worker and a patient; or demonstrating the intended information to a user for the purpose of comprehension.
- labeling means all labels or other means of written, printed, graphic, electronic, verbal, or demonstrative communication that is upon a pharmaceutical product or a dosage form or accompanying such pharmaceutical product or dosage form.
- a “medical care worker” means a worker in the health care field who may need or utilize information regarding an active agent, including a dosage form thereof, including information on safety, efficacy, dosing, administration, or pharmacokinetics.
- Examples of medical care workers include physicians, pharmacists, physician's assistants, nurses, aides, caretakers (which can include family members or guardians), emergency medical workers, and veterinarians.
- “Medication Guide” means an FDA-approved patient labeling for a pharmaceutical product conforming to the specifications set forth in 21 CFR 208 and other applicable regulations which contains information for patients on how to safely use a pharmaceutical product.
- a medication guide is scientifically accurate and is based on, and does not conflict with, the approved professional labeling for the pharmaceutical product under 21 CFR 201.57, but the language need not be identical to the sections of approved labeling to which it corresponds.
- a medication guide is typically available for a pharmaceutical product with special risk management information.
- patient or “individual” or “subject” means a mammal, including a human, for whom or which therapy is desired, and generally refers to the recipient of the therapy.
- patient package insert means information for patients on how to safely use a pharmaceutical product that is part of the FDA-approved labeling. It is an extension of the professional labeling for a pharmaceutical product that may be distributed to a patient when the product is dispensed which provides consumer-oriented information about the product in lay language, for example it may describe benefits, risks, how to recognize risks, dosage, or administration.
- “pharmaceutically acceptable” refers to a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
- pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
- “Pharmacologically active” as in a “pharmacologically active” (or “active”) derivative or analog, refers to a derivative or analog having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
- pharmaceutically acceptable salts include acid addition salts which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
- Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- a “product” or “pharmaceutical product” means a dosage form of an active agent plus published material, and optionally packaging.
- product insert means the professional labeling (prescribing information) for a pharmaceutical product, a patient package insert for the pharmaceutical product, or a medication guide for the pharmaceutical product.
- “professional labeling” or “prescribing information” means the official description of a pharmaceutical product approved by a regulatory agency (e.g., FDA or EMEA) regulating marketing of the pharmaceutical product, which includes a summary of the essential scientific information needed for the safe and effective use of the drug, such as, for example indication and usage; dosage and administration; who should take it; adverse events (side effects); instructions for use in special populations (pregnant women, children, geriatric, etc.); safety information for the patient, and the like.
- FDA regulatory agency
- published material means a medium providing information, including printed, audio, visual, or electronic medium, for example a flyer, an advertisement, a product insert, printed labeling, an internet web site, an internet web page, an internet pop-up window, a radio or television broadcast, a compact disk, a DVD, an audio recording, or other recording or electronic medium.
- risk means the probability or chance of adverse reaction, injury, or other undesirable outcome arising from a medical treatment.
- An “acceptable risk” means a measure of the risk of harm, injury, or disease arising from a medical treatment that will be tolerated by an individual or group. Whether a risk is “acceptable” will depend upon the advantages that the individual or group perceives to be obtainable in return for taking the risk, whether they accept whatever scientific and other advice is offered about the magnitude of the risk, and numerous other factors, both political and social.
- An “acceptable risk” of an adverse reaction means that an individual or a group in society is willing to take or be subjected to the risk that the adverse reaction might occur since the adverse reaction is one whose probability of occurrence is small, or whose consequences are so slight, or the benefits (perceived or real) of the active agent are so great.
- An “unacceptable risk” of an adverse reaction means that an individual or a group in society is unwilling to take or be subjected to the risk that the adverse reaction might occur upon weighing the probability of occurrence of the adverse reaction, the consequences of the adverse reaction, and the benefits (perceived or real) of the active agent.
- “At risk” means in a state or condition marked by a high level of risk or susceptibility. Risk assessment consists of identifying and characterizing the nature, frequency, and severity of the risks associated with the use of a product.
- safety means the incidence or severity of adverse events associated with administration of an active agent, including adverse effects associated with patient-related factors (e.g., age, gender, ethnicity, race, target illness, abnormalities of renal or hepatic function, co-morbid illnesses, genetic characteristics such as metabolic status, or environment) and active agent-related factors (e.g., dose, plasma level, duration of exposure, or concomitant medication).
- patient-related factors e.g., age, gender, ethnicity, race, target illness, abnormalities of renal or hepatic function, co-morbid illnesses, genetic characteristics such as metabolic status, or environment
- active agent-related factors e.g., dose, plasma level, duration of exposure, or concomitant medication
- treating refers to therapeutic applications to slow or stop progression of a disorder, prophylactic application to prevent development of a disorder, and/or reversal of a disorder.
- Reversal of a disorder differs from a therapeutic application which slows or stops a disorder in that with a method of reversing, not only is progression of a disorder completely stopped, cellular behavior is moved to some degree, toward a normal state that would be observed in the absence of the disorder.
- plasma is intended to mean the liquid component of blood that holds the blood cells in whole blood in suspension; this makes plasma the extracellular matrix of blood cells. It makes up about 55% of the body's total blood volume. It is mostly water (up to 95% by volume), and contains dissolved proteins (6-8%) (i.e.—serum albumins, globulins, and fibrinogen), glucose, clotting factors, electrolytes (Na + , Ca 2+ , Mg 2+ , HCO 3 ⁇ , Cl ⁇ , etc.), hormones, carbon dioxide (plasma being the main medium for excretory product transportation) and oxygen. This is in contrast to blood serum which is blood plasma without clotting factors. Further, plasma is derived from blood that is collected differently than when serum is collected, by allowing the blood to clot prior to centrifugation when collecting serum versus immediate centrifugation when collecting plasma.
- a method of treating conditions associated with a deficiency or absence of endogenous testosterone in a subject in need thereof who has adequately controlled blood pressure comprising: administering daily to the subject a defined dose of an oral pharmaceutical composition comprising testosterone undecanoate in a carrier comprising at least one lipophilic surfactant and at least one hydrophilic surfactant.
- the oral pharmaceutical composition is administered twice daily (BID). In some embodiments, the oral pharmaceutical composition is administered three times daily (TID). In some embodiments, the oral pharmaceutical composition is administered once daily (QD).
- the method further comprises:
- the first period of time is approximately three weeks.
- the method further comprises:
- the method further comprises: informing the subject that administration of the oral pharmaceutical composition may result in an increase in blood pressure.
- administration of the oral pharmaceutical composition results in an average increase of systolic blood pressure of 4.9 mm Hg based on ambulatory blood pressure monitoring.
- administration of the oral pharmaceutical composition results in an average increase of systolic blood pressure of 2.8 mm Hg based on blood pressure cuff measurements.
- the method further comprises: informing the subject that co-administration of the oral pharmaceutical composition with a prescription medication known to increase blood pressure and/or a nonprescription analgesic and/or a cold medication may result in additional increases in blood pressure.
- the method further comprises: monitoring the subject's blood pressure.
- the method further comprises: informing the subject that administration of the oral pharmaceutical composition may result in an increased risk of a major adverse cardiovascular event (MACE).
- MACE major adverse cardiovascular event
- the MACE is chosen from myocardial infarction, stroke and cardiovascular death.
- the subject has one or more cardiovascular risk factors or established cardiovascular disease.
- the subject is being co-administered a prescription medication known to increase blood pressure and/or a nonprescription analgesic and/or a cold medication may result in additional increases in blood pressure.
- the subject is not being administered a prescription medication known to increase blood pressure and/or a nonprescription analgesic and/or a cold medication may result in additional increases in blood pressure.
- the subject is not being treated with antihypertensive therapy.
- the subject is being treated with antihypertensive therapy.
- the subject does not have a history of hypertension.
- the subject has a history of hypertension.
- the subject is diagnosed with hypogonadal conditions associated with structural or genetic etiologies.
- the subject is diagnosed with primary hypogonadism. In some embodiments, the subject is diagnosed with testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
- the subject is diagnosed with hypogonadotropic hypogonadism. In some embodiments, the subject is diagnosed with gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
- LHRH luteinizing hormone-releasing hormone
- the subject is not diagnosed with age-related hypogonadism.
- the method further comprises: collecting the subject's blood sample;
- these steps are repeated until the serum testosterone concentration from blood collected 6 hours post-dose in the subject is between about 425 and about 970 ng/dL.
- the defined dose of testosterone undecanoate in the oral pharmaceutical composition is equivalent to about 150 mg of testosterone.
- the oral pharmaceutical composition administered comprises about 237 mg of testosterone undecanoate that equates to 150 mg of testosterone.
- the defined dose of testosterone undecanoate in the oral pharmaceutical composition is equivalent to about 200 mg of testosterone per dose.
- the oral pharmaceutical composition administered comprises about 316 mg of testosterone undecanoate that equates to 200 mg testosterone per dose.
- the defined dose of testosterone undecanoate in the oral pharmaceutical composition is equivalent to about 250 mg of testosterone per dose. In some embodiments, the oral pharmaceutical composition administered comprises about 396 mg of testosterone undecanoate that equates to 250 mg testosterone per dose.
- the defined dose of testosterone undecanoate in the oral pharmaceutical composition is equivalent to about 125 mg of testosterone per dose. In some embodiments, the oral pharmaceutical composition administered comprises about 198 mg of testosterone undecanoate that equates to 125 mg testosterone per dose.
- the defined dose of testosterone undecanoate in the oral pharmaceutical composition is equivalent to about 100 mg of testosterone per dose. In some embodiments, the oral pharmaceutical composition administered comprises about 158 mg of testosterone undecanoate that equates to 100 mg testosterone per dose.
- the dose of testosterone undecanoate in the administered oral pharmaceutical composition is increased by the equivalent of about 25 to about 75 mg of testosterone when the serum testosterone 6 hours after the dose (i.e., C 6 ) in the subject is less than about 425 ng/dL, and decreased by the equivalent of about 10 to about 75 mg of testosterone when the serum testosterone C 6 in the subject is greater than about 970 ng/dL.
- the dose of testosterone undecanoate is increased by about 40 mg to about 80 mg when the measured serum testosterone concentration in the subject is less than about 425 ng/dL.
- the dose of testosterone undecanoate is increased by the equivalent of about 40 to about 60 mg of testosterone when the serum testosterone C 6 in the subject is less than about 425 ng/dL. In some embodiments, the dose of testosterone undecanoate is increased by the equivalent of about 50 mg of testosterone when the serum testosterone C 6 in the subject is less than about 425 ng/dL.
- the dose of testosterone undecanoate is decreased by about 10 mg to about 40 mg when the measured serum testosterone concentration in the subject is greater than about 970 ng/dL.
- the dose of testosterone undecanoate is decreased by the equivalent of about 10 to about 60 mg of testosterone when the serum testosterone C 6 in the subject is greater than about 970 ng/dL. In some embodiments, the dose of testosterone undecanoate is decreased by the equivalent of about 25 to about 50 mg of testosterone when the serum testosterone C 6 in the subject is greater than about 970 ng/dL. In some embodiments, the dose of testosterone undecanoate is decreased by the equivalent of about 25 mg of testosterone when the serum testosterone C 6 in the subject is greater than about 970 ng/dL.
- the 237 mg dose of TU is increased to a 316 mg dose of TU when the subject's measured serum testosterone concentration is less than about 425 ng/dL or decreased to a dose of 198 mg of TU when the subject's measured serum testosterone concentration is greater than about 970 ng/dL.
- the 316 mg dose of TU is increased to a dose of 396 mg of TU when the subject's measured serum testosterone concentration is less than about 425 ng/dL or decreased to a dose of 237 mg of TU when the subject's measured serum testosterone concentration is greater than about 970 ng/dL.
- the 198 mg dose of TU is increased to a dose of 237 mg of TU when the subject's measured serum testosterone concentration is less than about 425 ng/dL or decreased to a dose of 158 mg of TU when the subject's measured serum testosterone concentration is greater than about 970 ng/dL.
- the 396 mg dose of TU is decreased to a dose of 316 mg of TU when the subject's measured serum testosterone concentration is greater than about 970 ng/dL.
- the 158 mg dose of TU is increased to a dose of 198 mg of TU when the subject's measured serum testosterone concentration is less than about 425 ng/dL or treatment is discontinued when the subject's measured serum testosterone concentration is greater than about 970 ng/dL.
- the dose adjustment scheme is as shown in Table 1.
- the blood is drawn at least 7 days after starting treatment and following dose adjustment.
- the blood is drawn 4-8 hours (i.e., C 4-8 ) after the administration of the dose. In some embodiments, the blood is drawn 5-7 hours after the administration of the dose. In some embodiments, the blood is drawn 6 hours after the administration of the dose (i.e., C 6 ).
- the circulating testosterone concentration is measured in serum.
- the serum testosterone level at 6 hours after administration (C 6 ) is a suitable approximation of C avg .
- the serum testosterone concentration is measured five to seven hours after administering the oral pharmaceutical composition.
- the serum testosterone concentration at 6 hours after administration of the morning dose is used to approximate C avg .
- the serum testosterone C avg is estimated on the basis of a single blood sample (i.e., C 6 serum T concentration). In some embodiments, the serum testosterone C avg is estimated on the basis of a single blood sample collected 4 to 8 hours after administering the oral pharmaceutical composition. In some embodiments, the serum testosterone C avg is estimated on the basis of a single blood sample collected 5 to 7 hours after administering the oral pharmaceutical composition. In some embodiments, the serum testosterone C avg is estimated on the basis of a single blood sample collected 6 hours after administering the oral pharmaceutical composition.
- the steady-state serum testosterone C avg is estimated based on the measurement of T in a single blood sample collected about 4 to 8 hours after oral T dose after at least seven days of daily treatment with the oral pharmaceutical composition. In some embodiments, the steady-state serum testosterone C avg is estimated based on the measurement of T in a single blood sample collected about 5 to 7 hours after oral T dose after at least seven days of daily treatment with the oral pharmaceutical composition. In some embodiments, the steady-state serum testosterone C avg is estimated based on the measurement of T in a single blood sample collected about 6 hours after oral T dose after at least seven days of daily treatment with the oral pharmaceutical composition.
- the average serum testosterone concentration (i.e., C avg ) is determined based on the measurement of T via an immunometric assay, or a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay.
- measuring the subject's testosterone concentration comprises estimating the subject's blood testosterone concentration by measuring the subject's serum testosterone concentration and dividing that concentration by a conversion factor.
- the conversion factor is between about 1.0 and about 1.4. In some embodiments, the conversion factor is between about 1.032 and about 1.396. In some embodiments, the conversion factor is 1.214. In some embodiments, if the sample is a serum sample, then dividing the T concentration measured in serum by 1.214 would yield the expected T concentration in NaF-EDTA plasma.
- the serum testosterone C avg is determined after at least 10 to 14 days of daily treatment with the oral pharmaceutical composition. In some embodiments, the serum testosterone C avg is determined after at least 30 days of daily treatment with the oral pharmaceutical composition. In some embodiments, the dose of oral pharmaceutical composition is titrated after 21 days of daily treatment.
- the dose of oral pharmaceutical composition is titrated after 56 days of daily treatment. In some embodiments, the dose of oral pharmaceutical composition is titrated after 105 days of daily treatment. In some embodiments, the dose of oral pharmaceutical composition is titrated after at least 30 days of daily treatment. In some embodiments, the dose of oral pharmaceutical composition is titrated after 35 days of daily treatment. In some embodiments, the dose of oral pharmaceutical composition is titrated after at least 60 days of daily treatment. In some embodiments, the dose of oral pharmaceutical composition is titrated after 70 days of daily treatment.
- the oral pharmaceutical composition is administered in close proximity to a meal (e.g., immediately prior or after a meal, or 15 minutes prior to after a meal or 30 minutes prior to or after a meal) wherein the meal contains at least about 15 g of fat. In some embodiments, the meal contains at least about 30 g of fat. In some embodiments, the meal contains at least about 45 g of fat.
- the oral pharmaceutical composition comprises a testosterone undecanoate solubilized in a carrier comprising at least one lipophilic surfactant and at least one hydrophilic surfactant in a total lipophilic surfactant to total hydrophilic surfactant ratio (w/w) falling in the range of about 6:1 to 3.5:1, which composition, upon once- or twice-daily oral administration, provides an average serum testosterone concentration at steady state falling in the range of about 425 to about 970 ng/dL.
- the composition comprises 15-30% (w/w) of the testosterone undecanoate. In some embodiments, the composition comprises 15-20% (w/w) of the testosterone undecanoate. In some embodiments, the composition comprises 18-22% (w/w) of the testosterone undecanoate. In some embodiments, the composition comprises 25-30% (w/w) of the testosterone undecanoate.
- the oral pharmaceutical composition comprises about 10-20 percent by weight of solubilized testosterone undecanoate, about 5-20 percent by weight of hydrophilic surfactant, about 50-70 percent by weight of lipophilic surfactant; and about 10-15 percent by weight of digestible oil, wherein the oral pharmaceutical composition is free of ethanol.
- the oral pharmaceutical composition comprises: about 15-20 percent by weight of solubilized testosterone undecanoate, about 5-20 percent by weight of hydrophilic surfactant, about 50-70 percent by weight of lipophilic surfactant; and about 10-15 percent by weight of digestible oil.
- the oral pharmaceutical composition comprises: about 15-20 percent by weight of solubilized testosterone undecanoate, about 5-20 percent by weight of hydrophilic surfactant, about 50-70 percent by weight of lipophilic surfactant; and about 1-10 percent by weight of polyethylene glycol 8000.
- the hydrophilic surfactant exhibits an HLB of 10 to 45. In some embodiments, the hydrophilic surfactant exhibits an HLB of 10 to 15.
- the hydrophilic surfactant is selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, hydrogenated castor oil ethoxylates, polyethylene glycol mono- and di-glycerol esters of caprylic, capric, palmitic and stearic acids, fatty acid ethoxylates, polyethylene glycol esters of alpha-tocopherol and its esters and combinations thereof.
- the hydrophilic surfactant is a hydrogenated castor oil ethoxylate.
- the hydrophilic surfactant is Cremophor RH 40 (polyoxyethyleneglycerol trihydroxystearate).
- the lipophilic surfactant exhibits an HLB of less than 10. In some embodiments, the lipophilic surfactant exhibits an HLB of less than 5. In some embodiments, the lipophilic surfactant exhibits an HLB of 1 to 2.
- the lipophilic surfactant is a fatty acid selected from the group consisting of octanoic acid, decanoic acid, undecanoic acid, lauric acid, myristic acid, palmitic acid, pamitoleic acid, stearic acid, oleic acid, linoleic acid, alpha- and gamma linolenic acid, arachidonic acid, and combinations thereof.
- the lipophilic surfactant is chosen from mono- and/or di-glycerides of fatty acids, such as glyceryl distearate, Imwitor 988 (glyceryl mono-/di-caprylate), Imwitor 742 (glyceryl mono-di-caprylate/caprate), Imwitor 308 (glyceryl mono-caprylate), Imwitor 191 (glyceryl mono-stearate), Softigen 701 (glyceryl mono-/di-ricinoleate), Capmul MCM (glyceryl caprylate/caprate), Capmul MCM(L) (liquid form of Capmul MCM), Capmul GMO (glyceryl mono-oleate), Capmul GDL (glyceryl dilaurate), Maisine (glyceryl mono-linoleate), Peceol (glyceryl mono-oleate), Myverol 18-92 (distilled monoglycerides from sunflower oil) and Myverol 18-06 (
- the lipophilic surfactant is chosen from acetic, succinic, lactic, citric and/or tartaric esters of mono- and/or di-glycerides of fatty acids, for example, Myvacet 9-45 (distilled acetylated monoglycerides), Miglyol 829 (caprylic/capric diglyceryl succinate), Myverol SMG (mono/di-succinylated monoglycerides), Imwitor 370 (glyceryl stearate citrate), Imwitor 375 (glyceryl monostearate/citrate/lactate) and Crodatem T22 (diacetyl tartaric esters of monoglycerides); Propylene glycol mono- and/or di-esters of fatty acids, for example, Lauroglycol (propylene glycol monolaurate), Mirpyl (propylene glycol monomyristate), Captex 200 (propylene glycol dicaprylate/dicaprate
- Sorbitan esters of fatty acids for example, Span 20 (sorbitan monolaurate), Crill 1 (sorbitan monolaurate) and Crill 4 (sorbitan mono-oleate); Transesterification products of natural or hydrogenated vegetable oil triglyceride and a polyalkylene polyol (HLB ⁇ 10), e.g. Labrafil M1944CS (polyoxyethylated apricot kernel oil), Labrafil M2125CS (polyoxyethylated corn oil) and Gelucire 37/06 (polyoxyethylated hydrogenated coconut); Alcohol ethyoxylates (HLB ⁇ 10), e.g.
- Volpo N3 polyoxyethylated (3) oleyl ether
- Brij 93 polyoxyethylated (2) oleyl ether
- Marlowet LA4 polyoxyethylated (4) lauryl ether
- the lipophilic surfactant is glyceryl monolinoleate.
- the oral pharmaceutical composition further includes digestible oil.
- a digestible oil is defined herein as an oil that is capable of undergoing de-esterification or hydrolysis in the presence of pancreatic lipase in vivo under normal physiological conditions.
- the digestible oil is a vegetable oil selected from the group consisting of soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, sunflower seed oil, coconut oil, palm oil, rapeseed oil, black currant oil, evening primrose oil, grape seed oil, wheat germ oil, sesame oil, avocado oil, almond oil, borage oil, peppermint oil and apricot kernel oil.
- digestible oils may be complete glycerol triesters of medium chain (C 7 -C 13 ) or long chain (C 14 -C 22 ) fatty acids with low molecular weight (up to C 6 ) mono-, di- or polyhydric alcohols.
- digestible oils for use the oral pharmaceutical composition include: vegetable oils (e.g., soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, sunflower seed oil, coconut oil, palm oil, rapeseed oil, black currant oil, evening primrose oil, grape seed oil, wheat germ oil, sesame oil, avocado oil, almond, borage, peppermint and apricot kernel oils) and animal oils (e.g., fish liver oil, shark oil and mink oil).
- the digestible oil is a vegetable oil.
- the vegetable oil is soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, sunflower seed oil, coconut oil, palm oil, rapeseed oil, evening primrose oil, grape seed oil, wheat germ oil, sesame oil, avocado oil, almond oil, borage oil, peppermint oil, apricot kernel oil, or combinations thereof.
- Particular digestible oils are those with high gamma-linolenic acid (GLA) content such as, black currant oil, primrose oil and borage oil, as well as any other digestible oil that can be enriched in GLA acid through enzymatic processes.
- GLA gamma-linolenic acid
- the oral pharmaceutical composition is filled into a hard or soft gelatin capsule.
- the oral pharmaceutical composition is a liquid, semi-solid or solid dosage form.
- the oral pharmaceutical compositions administered in the present invention are liquid or semi-solid at ambient temperatures.
- these pharmaceutical compositions can be transformed into solid dosage forms through adsorption onto solid carrier particles, such as silicon dioxide, calcium silicate or magnesium aluminometasilicate to obtain free-flowing powders that can be either filled into hard capsules or compressed into tablets.
- solid carrier particles such as silicon dioxide, calcium silicate or magnesium aluminometasilicate
- the term “solubilized” herein should be interpreted to describe an active pharmaceutical ingredient (API), which is dissolved in a liquid solution or which is uniformly dispersed in a solid carrier.
- API active pharmaceutical ingredient
- sachet type dosage forms can be formed and used.
- the oral pharmaceutical composition is filled into a hard or soft gelatin capsule.
- the oral pharmaceutical composition exhibits a percent (%) in vitro dissolution profile in 5% Triton X-100 solution in phosphate buffer, pH 6.8, indicating release from the composition of substantially all of the solubilized testosterone undecanoate within about 2 hours.
- the oral pharmaceutical composition exhibits a percent (%) in vitro dissolution profile in 5% Triton X-100 solution in phosphate buffer, pH 6.8, indicating release from the composition of substantially all of the solubilized testosterone undecanoate within about 1 hour.
- the composition is free of monohydric alcohol.
- the monohydric alcohol is chosen from C 2 -C 18 aliphatic or aromatic alcohol. In some embodiments, the monohydric alcohol is chosen from ethanol and benzyl alcohol.
- Optional cosolvents suitable with the oral pharmaceutical composition are, for example, water, short chain mono-, di-, and polyhydric alcohols, such as ethanol, benzyl alcohol, glycerol, propylene glycol, propylene carbonate, polyethylene glycol (PEG) with an average molecular weight of about 200 to about 10,000, diethylene glycol monoethyl ether (e.g., Transcutol HP), and combinations thereof.
- the compositions contain between 0% and 10% (w/w) of polyethylene glycol with an average molecular weight of about 8,000 (PEG-8000).
- the compositions contain between 5% and 10% (w/w) of PEG-8000.
- the oral pharmaceutical composition comprises at least one hydrophilic surfactant comprises Cremophor RH 40 (polyoxyethyleneglycerol trihydroxystearate).
- the lipophilic surfactant comprises oleic acid.
- the oral pharmaceutical composition comprises about 18 to 22 percent by weight of a solubilized testosterone undecanoate.
- the testosterone undecanoate is solubilized in a carrier substantially free of ethanol.
- the oral pharmaceutical composition comprises 15 to 17 percent by weight of the at least one hydrophilic surfactant.
- the oral pharmaceutical composition comprises 50 to 55 percent by weight of the at least one lipophilic surfactant.
- the oral pharmaceutical composition comprises about 19.8 percent by weight of solubilized testosterone undecanoate, about 51.6 percent by weight of oleic acid, about 16.1 percent by weight of polyoxyethylene (40) hydrogenated castor oil, about 10 percent by weight of borage seed oil, about 2.5 percent by weight of peppermint oil, and about 0.03 percent by weight of butylated hydroxytoluene (BHT).
- solubilized testosterone undecanoate about 51.6 percent by weight of oleic acid
- polyoxyethylene (40) hydrogenated castor oil about 10 percent by weight of borage seed oil, about 2.5 percent by weight of peppermint oil
- BHT butylated hydroxytoluene
- each morning and evening dose initially comprises about 237 mg of testosterone undecanoate.
- the oral pharmaceutical composition comprises about 15 percent by weight of testosterone undecanoate, about 63 percent by weight of glyceryl mono-linoleate, about 16 percent by weight of polyoxyethylene (40) hydrogenated castor oil, and about 6 percent by weight of polyethylene glycol having a molecular weight of about 8000 g/mol (PEG 8000).
- the oral pharmaceutical composition comprises one or more additional therapeutic agents.
- the additional therapeutic agents are selected from the group consisting of a synthetic progestin, an inhibitor of type-I and/or type II 5 ⁇ -reductase (e.g., finasteride and dutasteride), an inhibitor of CYP3A4, thiazide diuretics, and calcium channel blockers, and combinations thereof.
- the one or more additional therapeutic agents comprises a second testosterone ester.
- the agent is borage oil.
- the agent is peppermint oil and related substances such as menthol and menthol esters.
- the oral pharmaceutical composition comprises one or more additional component(s) that may biochemically modulate (1) testosterone ester absorption, (2) testosterone ester metabolism to testosterone, and/or (3) metabolism of testosterone to dihydrotestosterone (DHT).
- additional component(s) may biochemically modulate (1) testosterone ester absorption, (2) testosterone ester metabolism to testosterone, and/or (3) metabolism of testosterone to dihydrotestosterone (DHT).
- DHT dihydrotestosterone
- the inclusion of medium to long chain fatty acid esters can enhance testosterone ester absorption. In this way, more testosterone ester may stave off hydrolysis in the gut and enter the blood stream. In other words, the fatty acid ester may competitively inhibit esterases that would otherwise metabolize the testosterone ester.
- examples of other esters or combinations thereof include botanical extracts or benign esters used as food additives (e.g., propylparaben, octylacetate and ethylacetate).
- Other components that can modulate testosterone ester absorption include “natural” and synthetic inhibitors of 5 ⁇ -reductase, which is an enzyme present in enterocytes and other tissues that catalyzes the conversion of T to DHT. Complete or partial inhibition of this conversion may both increase and sustain increased plasma levels of T after oral dosing with testosterone ester while concomitantly reducing plasma DHT levels.
- Borage oil which contains a significant amount of the 5 ⁇ -reductase inhibitor, gamma-linolenic acid (GLA), is an example of a “natural” modulator of testosterone ester metabolism.
- GLA gamma-linolenic acid
- GLA could be added directly as a separate component of a testosterone ester formulation of the invention.
- any digestible oil as listed above can be enzymatically enriched in GLA.
- Many natural inhibitors of 5 ⁇ -reductase are known in the art (e.g., epigallocatechin gallate, a catechin derived primarily from green tea and saw palmetto extract from berries of the Serenoa repens species, phytosterols and lycopene), all of which may be suitable in the present invention.
- Non-limiting examples of synthetic 5 ⁇ -reductase inhibitors suitable for use in the present invention include compounds such as finasteride, dutasteride and the like.
- ABPM 24-hour ambulatory blood pressure monitoring
- the blood pressure measured in a clinic setting using blood pressure cuff measurements rose during the course of treatment with a mean systolic increase of 2.8 mmHg (95% CI 1.0, 4.6) and a mean diastolic increase of 0.6 mmHg (95% CI -0.7, 1.9) at the final on-treatment visit (Day 139).
- JATENZO The efficacy and safety of JATENZO was evaluated in 166 adult hypogonadal males in an open label study of approximately 4 months duration (NCT02722278). The study included a Screening Phase, a Treatment Titration Phase, and a Treatment Maintenance Phase.
- JATENZO was taken orally at a starting dose of 237 mg twice per day with meals. The dose was adjusted on Days 21 and 56 between a minimum of 158 mg twice per day and a maximum of 396 mg twice per day on the basis of the average testosterone concentration obtained over 24 hours post-morning dose.
- the primary endpoint was the percentage of patients with mean plasma total testosterone concentration (C avg ) over 24-hours within the normal eugonadal range on the final PK visit of the study.
- Secondary endpoints were the percentage of patients with a maximum total testosterone concentration (Cmax) above three predetermined limits: less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL.
- the percentage of patients who received JATENZO and had Cmax less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL at the final PK visit were 83%, 3%, and 3%, respectively.
- the testosterone concentrations were not measured in serum but the effects of different sample preparation conditions were accounted for in data analysis of the results shown here.
- the titration scheme for use in clinical practice is based on serum total testosterone.
Abstract
Description
-
- diuretics, such as bumetanide, chlorothiazide, chlorthalidone, ethacrynate, furosemide, indapamide, hydrochlorothiazide (HCTZ), methyclothiazide, metolazone, or torsemide;
- angiotensin-converting enzyme (ACE) inhibitors, such as benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril, perindopril, quinapril hydrochloride, ramipril, or trandolapril;
- angiotensin II receptor blockers, such as candesartan or losartan;
- calcium channel blockers such as amlodipine, clevidipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, or verapamil;
- alpha blockers, such as doxazosin, terazosin or prazosin;
- beta blockers, such as acebutolol, atenolol, bisoprolol fumarate, carvedilol, esmilol, labetalol, metoprolol tartrate and metoprolol succinate, nadolol, nebivolol, penbutolol sulfate, propranolol, sotalol, or bisoprolol;
- aldosterone antagonists, such as spironolactone or eplerenone,
- epithelial Na-channel blockers, such as amiloride and triamterene,
- peripheral adrenergic inhibitors such as guanadrel, guanethidine monosulfate, or reserpine;
- renin inhibitors, such as aliskiren;
- vasodilators, such as hydralazine and minoxidil; and
- central-acting agents such as clonidine, guanfacine or methyldopa, and combinations thereof.
-
- measuring the serum testosterone concentration in the subject; and
- if the measured serum testosterone concentration is less than about 425 ng/dL, increasing the dose of testosterone undecanoate administered;
- if the measured serum testosterone concentration is greater than about 970 ng/dL decreasing the dose of testosterone undecanoate; and
- if the measured serum testosterone concentration is between about 425 ng/dL and about 970 ng/dL, maintaining the dose of testosterone undecanoate administered.
TABLE 1 | ||
Testosterone Concentration in | ||
Serum From Plain (Red-Top) | Current Dose | New Dose |
Tube Drawn 6 hours After Dose | (mg, BID) | (mg, BID) |
<425 | ng/dL | 158 | 198 |
198 | 237 | ||
237 | 316 | ||
316 | 398 |
425-970 | ng/dL | No Dose Change |
>970 | ng/dL | 396 | 316 |
316 | 237 | ||
237 | 198 | ||
198 | 158 | ||
158 | Discontinue Treatment | ||
Ingredients | mg/capsule | %, w/w | |
Testosterone Undecanoate | 158.3 | 19.8 | |
Oleic Acid | 413.1 | 51.6 | |
Cremophor RH 40 | 128.4 | 16.1 | |
Borage Seed Oil | 80.0 | 10 | |
Peppermint Oil | 20.0 | 2.5 | |
BHT | 0.2 | 0.03 | |
Total | 800 | 100.03 | |
Formulation B
Ingredients | mg/capsule | %, w/w | |
Testosterone Undecanoate | 158.3 | 19.8 | |
Oleic Acid | 412.5 | 51.6 | |
Cremophor RH 40 | 128.4 | 16.0 | |
Peppermint Oil | 20.0 | 2.5 | |
Borage Seed Oil + 0.03% BHT | 80.0 | 10 | |
Ascorbyl Palmitate | 0.8 | 0.1 | |
Total | 800 | 100 | |
Formulation C
Ingredients | mg/capsule | %, w/w | |
Testosterone Undecanoate | 120 | 15 | |
Cremophor RH 40 | 128 | 16 | |
Maisine 35-1 | 504 | 63 | |
Polyethylene Glycol 8000 | 48 | 6 | |
TOTAL | 800 | 100 | |
Claims (27)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/382,835 US11564933B2 (en) | 2019-04-12 | 2019-04-12 | Methods of treating testosterone deficiency |
US18/086,994 US20230218635A1 (en) | 2019-04-12 | 2022-12-22 | Methods of treating testosterone deficiency |
US18/171,790 US20230233578A1 (en) | 2019-04-12 | 2023-02-21 | Methods of treating testosterone deficiency |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/382,835 US11564933B2 (en) | 2019-04-12 | 2019-04-12 | Methods of treating testosterone deficiency |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/086,994 Continuation US20230218635A1 (en) | 2019-04-12 | 2022-12-22 | Methods of treating testosterone deficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200323880A1 US20200323880A1 (en) | 2020-10-15 |
US11564933B2 true US11564933B2 (en) | 2023-01-31 |
Family
ID=72748816
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/382,835 Active US11564933B2 (en) | 2019-04-12 | 2019-04-12 | Methods of treating testosterone deficiency |
US18/086,994 Pending US20230218635A1 (en) | 2019-04-12 | 2022-12-22 | Methods of treating testosterone deficiency |
US18/171,790 Pending US20230233578A1 (en) | 2019-04-12 | 2023-02-21 | Methods of treating testosterone deficiency |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/086,994 Pending US20230218635A1 (en) | 2019-04-12 | 2022-12-22 | Methods of treating testosterone deficiency |
US18/171,790 Pending US20230233578A1 (en) | 2019-04-12 | 2023-02-21 | Methods of treating testosterone deficiency |
Country Status (1)
Country | Link |
---|---|
US (3) | US11564933B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082384A2 (en) | 2009-12-31 | 2011-07-07 | Differential Drug Development Associates, Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
CN105188670B (en) | 2013-03-15 | 2018-11-02 | 马留斯医药有限责任公司 | Emulsion formulations |
BR112023024162A2 (en) * | 2021-05-19 | 2024-02-06 | Marius Pharmaceuticals Llc | PREFERRED ORAL THERAPY WITH TESTOSTERONE UNDECANOATE TO OBTAIN TESTOSTERONE REPLACEMENT TREATMENT |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6652880B1 (en) * | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
WO2011129812A1 (en) * | 2010-04-12 | 2011-10-20 | Clarus Therapeutics, Inc. | Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same |
US20120148675A1 (en) * | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
-
2019
- 2019-04-12 US US16/382,835 patent/US11564933B2/en active Active
-
2022
- 2022-12-22 US US18/086,994 patent/US20230218635A1/en active Pending
-
2023
- 2023-02-21 US US18/171,790 patent/US20230233578A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6652880B1 (en) * | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
WO2011129812A1 (en) * | 2010-04-12 | 2011-10-20 | Clarus Therapeutics, Inc. | Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same |
US20120148675A1 (en) * | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
Non-Patent Citations (9)
Also Published As
Publication number | Publication date |
---|---|
US20200323880A1 (en) | 2020-10-15 |
US20230218635A1 (en) | 2023-07-13 |
US20230233578A1 (en) | 2023-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11311555B2 (en) | High-strength testosterone undecanoate compositions | |
RU2429850C2 (en) | Pharmaceutical delivery systems for hydrophobic therapeutic agents and compositions containing it | |
US20230218635A1 (en) | Methods of treating testosterone deficiency | |
KR101460871B1 (en) | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same | |
US20220088034A1 (en) | Methods of treating testosterone deficiency | |
US20210220374A1 (en) | Methods of treating testosterone deficiency | |
US20220265678A1 (en) | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment | |
US20200038411A1 (en) | Methods of treating testosterone deficiency | |
US20190365780A1 (en) | High-strength testosterone undecanoate compositions | |
US20230398128A1 (en) | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment | |
US11931367B2 (en) | Oral (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate therapy | |
RU2642244C2 (en) | Oral pharmaceutical compositions of testosterone esters and method for testosterone shortage treatment with their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: U.S. BANK NATIONAL ASSOCIATION, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:CLARUS THERAPEUTICS, INC.;REEL/FRAME:052099/0349 Effective date: 20200312 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: CLARUS THERAPEUTICS, INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUDLEY, ROBERT E.;DANOFF, THEODORE;REEL/FRAME:054642/0333 Effective date: 20190508 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: TOLMAR, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CLARUS THERAPEUTICS, INC.;REEL/FRAME:061774/0516 Effective date: 20221027 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
AS | Assignment |
Owner name: CLARUS THERAPEUTICS, INC., ILLINOIS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION;REEL/FRAME:062000/0052 Effective date: 20221130 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |